Germline mutations in the BRCA1 and BRCA2 breast cancer susceptibility genes have been associated with up to 15% of TNBC, and TNBC accounts for 70% of breast tumors arising in BRCA1 mutation carriers and 16–23% of breast tumors in BRCA2 carriers (8). The gene discussed is BRCA2; the disease is breast neoplasm.